Literature DB >> 18187137

Cystatin C--a marker of peripheral atherosclerotic disease?

J Arpegård1, J Ostergren, U de Faire, L-O Hansson, P Svensson.   

Abstract

UNLABELLED: It has been suggested that Cystatin C, besides its function as a marker of glomerular filtration, could be an independent marker of cardiovascular disease. However, studies on this topic are few and results have been indecisive. Our aim was to further investigate the subject of Cystatin C as an independent marker of peripheral atherosclerotic disease.
METHOD: Blood samples were analysed for serum Cystatin C, IL6, CRP and creatinine in 103 males with peripheral arterial disease (PAD) and 96 controls matched for age and sex. Creatinine clearance (CCr) was calculated according to Cockcroft's formula and estimated glomerular filtration rate (eGFR) was calculated according to MDRD formula.
RESULTS: Cystatin C-concentration was higher in PAD-patients compared to controls; 1.09+/-0.40 vs. 0.95+/-0.17 mg/L (p<0.01). There was no difference in CCr; 81+/-27 vs. 82+/-22 mL/min or eGFR; 76+/-21 vs. 79+/-14 mL/min. Cystatin C correlated to CCr, logIL-6 and logCRP in both patients (r=-0.60, p<0.001), (r=0.35, p<0.001) and (r=0.30, p<0.01) and controls (-0.44, p<0.001), (0.38, p<0.001) and (r=0.32, p<0.01), respectively. In an analysis of covariance, corrected for difference in eGFR, Cystatin C remained higher in PAD-patients compared to controls; 1.09 (C.I. 1.04-1.14) vs. 0.96 (C.I. 0.90-1.01).
CONCLUSION: Cystatin C-concentration, corrected for differences in eGFR, IL-6 and CRP values, is higher in PAD-patients compared to controls. Our finding suggests that Cystatin C may be an independent marker of atherosclerotic disease apart from its relation to kidney function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187137     DOI: 10.1016/j.atherosclerosis.2007.11.025

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  21 in total

Review 1.  Association of cystatin C with adverse outcomes.

Authors:  Magdalena Madero; Mark J Sarnak
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-05       Impact factor: 2.894

2.  Impact of cystatin C levels on infarct size and hemorrhage volume in acute cerebral stroke.

Authors:  Dongfang Xiao; Hailong Liu; Hong Zhang; Yumin Luo
Journal:  J Neurol       Date:  2012-02-18       Impact factor: 4.849

3.  Longitudinal proteomics analysis in the immediate microenvironment of islet allografts during progression of rejection.

Authors:  Oscar Alcazar; Luis F Hernandez; Ernesto S Nakayasu; Paul D Piehowski; Charles Ansong; Midhat H Abdulreda; Peter Buchwald
Journal:  J Proteomics       Date:  2020-05-20       Impact factor: 4.044

4.  The association between renal function biomarkers and subclinical cardiovascular measures in African Caribbean families.

Authors:  Hu Li; Allison Kuipers; Candace M Kammerer; Clareanne H Bunker; Lewis H Kuller; Iva Miljkovic; Alan L Patrick; Victor W Wheeler; Joseph M Zmuda
Journal:  Ethn Dis       Date:  2013       Impact factor: 1.847

5.  Platelet-derived miR-92a downregulates cysteine protease inhibitor cystatin C in type II diabetic lower limb ischemia.

Authors:  Yunfeng Zhang; Qiang Guan; Xing Jin
Journal:  Exp Ther Med       Date:  2015-04-01       Impact factor: 2.447

6.  Serum cystatin C and the incidence of hypertension in type 1 diabetes mellitus.

Authors:  Karine Sahakyan; Barbara E K Klein; Kristine E Lee; Michael Y Tsai; Ronald Klein
Journal:  Am J Hypertens       Date:  2010-09-30       Impact factor: 2.689

7.  Cystatin C, cardiometabolic risk, and body composition in severely obese children.

Authors:  Pilar Codoñer-Franch; Esther Ballester-Asensio; Lorena Martínez-Pons; Jorge Vallecillo-Hernández; Almudena Navarro-Ruíz; Ramón del Valle-Pérez
Journal:  Pediatr Nephrol       Date:  2010-11-19       Impact factor: 3.714

8.  Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease.

Authors:  Grazina Urbonaviciene; Guo Ping Shi; Sigitas Urbonavicius; Eskild W Henneberg; Jes S Lindholt
Journal:  Atherosclerosis       Date:  2011-02-18       Impact factor: 5.162

Review 9.  Matrix metalloproteinases and peripheral arterial disease.

Authors:  Chiara Busti; Emanuela Falcinelli; Stefania Momi; Paolo Gresele
Journal:  Intern Emerg Med       Date:  2009-07-21       Impact factor: 3.397

10.  Kidney function estimated from serum creatinine and cystatin C and peripheral arterial disease in NHANES 1999-2002.

Authors:  Elizabeth Selvin; Anna Köttgen; Josef Coresh
Journal:  Eur Heart J       Date:  2009-05-31       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.